- Conditions
- Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
- Interventions
- Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery, Questionnaire Administration
- Biological · Procedure · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 3,295
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Larynx, Lip, Oral Cavity and Pharynx
- Interventions
- Nivolumab, Ipilimumab, Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy
- Biological · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Head and Neck Squamous Cell Carcinoma, Brain Metastases
- Interventions
- Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), 18F-fluoromisonidazole
- Procedure · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Esophageal Cancer, Stomach Cancer
- Interventions
- KD019
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mucositis
- Interventions
- Low Level Laser Therapy
- Device
- Lead sponsor
- David A. Clump, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Head and Neck Cancer
- Interventions
- Taxotere, Surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer
- Interventions
- IM-1617
- Drug
- Lead sponsor
- Immunome, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 1 more
- Conditions
- Neoplasms
- Interventions
- GSK3326595, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Miami, Florida • New York, New York + 3 more
- Conditions
- Head and Neck Cancer
- Interventions
- Gefitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Head and Neck Cancer
- Interventions
- gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, needle biopsy
- Genetic · Other · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Barretts Esophagus, Esophageal Cancer
- Interventions
- Cryospray Ablation
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Head And Neck Cancer
- Interventions
- Placebo, Armodafinil, Minocycline, Bupropion
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Multiple Myeloma, Parathyroid Neoplasms, Renal Cancer, Thyroid Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer
- Interventions
- denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 12
- States / cities
- Encinitas, California • New Haven, Connecticut • Salisbury, Maryland + 9 more
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
- Interventions
- LY4101174
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Orlando, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- VX15/2503, Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
- Interventions
- Ad5CMV-p53 gene, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 230
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 178 more
- Conditions
- Larynx Cancer
- Interventions
- questionnaires and standardized, digital voice recording
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm, Melanoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Interventions
- Internet-Based Intervention, Interview, Questionnaire Administration
- Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 20 Years to 39 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Neoplasms, Malignant, Breast Neoplasm, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasm, Head and Neck Neoplasms
- Interventions
- Carlo Erba Ink Injection, EPR Oximetry Measurement
- Device · Other
- Lead sponsor
- Philip Schaner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Cancer
- Interventions
- trastuzumab, tipifarnib
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 2
- States / cities
- Fort Sam Houston, Texas • San Antonio, Texas
- Conditions
- Cancer, Thoracic Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer
- Interventions
- Blood Specimen Collection, Stool Specimen Collection, Quality of Life (QOL) Questionnaires
- Procedure · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Radiation Induced Oral Mucositis
- Interventions
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Placebo, Intensity-Modulated Radiation Therapy, Cisplatin
- Drug · Radiation
- Lead sponsor
- Galera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 55 more
- Conditions
- HIV Infections, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Group Meeting (Focus Group), Questionnaires
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California